The primary long-term endpoint was reached by 15 % of the patients in the CoQ10 group versus 26 % in the placebo group ( hazard ratio : 0.50 ; 95 % confidence interval : 0.32 to 0.80 ; p = 0.003 ) by intention-to-treat analysis .